Clinical characteristics of validation cohort used for mRNA ISH (N = 132)
| . | CSF1R− ISH . | CSF1R+ ISH . | P . |
|---|---|---|---|
| N (%) | 69 (52) | 63 (48) | |
| Median age, y (range) | 35 (15-80) | 43 (16-77) | NS |
| Sex, male, no. (%) | 49 | 57 | NS |
| Histology, % | .003 | ||
| Nodular sclerosis | 97 | 81 | |
| Other | 3 | 19 | |
| Stage, % | NS | ||
| I | 9 | 5 | |
| II | 54 | 44 | |
| III | 23 | 29 | |
| IV | 14 | 22 | |
| B-symptoms (%) | 39 | 54 | NS |
| Median mass size, cm | 8.0 | 6.9 | NS |
| ≥ 10 cm, (%) | 35 | 29 | NS |
| Treatment | NS | ||
| ABVD type ± radiation (%) | 100 | 98 | |
| Extended field radiation alone (%) | 0 | 2 | |
| CD68− IHC elevated (CD68+ > 5%) | 65 | 83 | .030 |
| . | CSF1R− ISH . | CSF1R+ ISH . | P . |
|---|---|---|---|
| N (%) | 69 (52) | 63 (48) | |
| Median age, y (range) | 35 (15-80) | 43 (16-77) | NS |
| Sex, male, no. (%) | 49 | 57 | NS |
| Histology, % | .003 | ||
| Nodular sclerosis | 97 | 81 | |
| Other | 3 | 19 | |
| Stage, % | NS | ||
| I | 9 | 5 | |
| II | 54 | 44 | |
| III | 23 | 29 | |
| IV | 14 | 22 | |
| B-symptoms (%) | 39 | 54 | NS |
| Median mass size, cm | 8.0 | 6.9 | NS |
| ≥ 10 cm, (%) | 35 | 29 | NS |
| Treatment | NS | ||
| ABVD type ± radiation (%) | 100 | 98 | |
| Extended field radiation alone (%) | 0 | 2 | |
| CD68− IHC elevated (CD68+ > 5%) | 65 | 83 | .030 |
NS indicates not significant.